BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 26563205)

  • 1. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
    Xie T; Taylor LS
    Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Release of Celecoxib from High Drug Loading Amorphous Solid Dispersions Formulated with Polyacrylic Acid and Cellulose Derivatives.
    Xie T; Taylor LS
    Mol Pharm; 2016 Mar; 13(3):873-84. PubMed ID: 26791934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.
    Jackson MJ; Kestur US; Hussain MA; Taylor LS
    Mol Pharm; 2016 Jan; 13(1):223-31. PubMed ID: 26618718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions.
    Knopp MM; Nguyen JH; Becker C; Francke NM; Jørgensen EB; Holm P; Holm R; Mu H; Rades T; Langguth P
    Eur J Pharm Biopharm; 2016 Apr; 101():145-51. PubMed ID: 26899127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.
    Konno H; Handa T; Alonzo DE; Taylor LS
    Eur J Pharm Biopharm; 2008 Oct; 70(2):493-9. PubMed ID: 18577451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions.
    Chen Y; Liu C; Chen Z; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
    Mol Pharm; 2015 Feb; 12(2):576-89. PubMed ID: 25535667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Temperature and Moisture on the Physical Stability of Binary and Ternary Amorphous Solid Dispersions of Celecoxib.
    Xie T; Taylor LS
    J Pharm Sci; 2017 Jan; 106(1):100-110. PubMed ID: 27476771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution and precipitation behavior of amorphous solid dispersions.
    Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS
    J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
    Purohit HS; Taylor LS
    Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Behavior of Resveratrol Solid Dispersions Upon Addition to Aqueous media.
    Wegiel LA; Mosquera-Giraldo LI; Mauer LJ; Edgar KJ; Taylor LS
    Pharm Res; 2015 Oct; 32(10):3324-37. PubMed ID: 25975588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions.
    Knopp MM; Nguyen JH; Mu H; Langguth P; Rades T; Holm R
    AAPS J; 2016 Mar; 18(2):416-23. PubMed ID: 26769250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers.
    Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
    J Pharm Sci; 2013 Jan; 102(1):171-84. PubMed ID: 23132686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution performance of binary amorphous drug combinations--Impact of a second drug on the maximum achievable supersaturation.
    Trasi NS; Taylor LS
    Int J Pharm; 2015 Dec; 496(2):282-90. PubMed ID: 26456250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.
    Prasad D; Chauhan H; Atef E
    J Pharm Sci; 2014 Nov; 103(11):3511-3523. PubMed ID: 25196860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.
    Qian F; Wang J; Hartley R; Tao J; Haddadin R; Mathias N; Hussain M
    Pharm Res; 2012 Oct; 29(10):2765-76. PubMed ID: 22315020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pairwise polymer blends for oral drug delivery.
    Marks JA; Wegiel LA; Taylor LS; Edgar KJ
    J Pharm Sci; 2014 Sep; 103(9):2871-2883. PubMed ID: 24823790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of polymers on the crystallization and phase transition kinetics of amorphous nifedipine during dissolution in aqueous media.
    Raina SA; Alonzo DE; Zhang GG; Gao Y; Taylor LS
    Mol Pharm; 2014 Oct; 11(10):3565-76. PubMed ID: 25185035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
    Baghel S; Cathcart H; O'Reilly NJ
    Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion.
    Knopp MM; Wendelboe J; Holm R; Rades T
    Eur J Pharm Biopharm; 2018 Sep; 130():290-295. PubMed ID: 30064702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.